Transplantable Leukemias
| Donors . | Donor Organ . | No. of Donors . | No. of Recipients . | Observation Time (wk) . | No. of Recipients With Leukemia . |
|---|---|---|---|---|---|
| bcr-ABL/bcr+ | SP | 2 | 4 | 6-12 | 3 |
| BM | 2 | 4 | 6-12 | 4 | |
| bcr-ABL/bcr− | SP | 2 | 4 | 6-12 | 4 |
| BM | 2 | 4 | 6-12 | 4 | |
| Control | SP | 5 | 10 | 6-12 | 0 |
| BM | 5 | 10 | 6-12 | 0 |
| Donors . | Donor Organ . | No. of Donors . | No. of Recipients . | Observation Time (wk) . | No. of Recipients With Leukemia . |
|---|---|---|---|---|---|
| bcr-ABL/bcr+ | SP | 2 | 4 | 6-12 | 3 |
| BM | 2 | 4 | 6-12 | 4 | |
| bcr-ABL/bcr− | SP | 2 | 4 | 6-12 | 4 |
| BM | 2 | 4 | 6-12 | 4 | |
| Control | SP | 5 | 10 | 6-12 | 0 |
| BM | 5 | 10 | 6-12 | 0 |
Nonirradiated NOD/SCID mice were injected intravenously with 106 cells from lymphoid organs of bcr-ABL/bcr+, bcr-ABL/bcr−, and control mice. Mice were scored for the development of leukemia by blood smears.
Abbreviations: SP, spleen; BM, bone marrow.